Tissue metabolites in diffuse glioma and their modulations by IDH1 mutation, histology and treatment скачать в хорошем качестве

Tissue metabolites in diffuse glioma and their modulations by IDH1 mutation, histology and treatment

In the run-up to next week's #BrainAwarnessWeek, Prof. Dr. Ghazaleh Tabatabai, Dr. Christoph Trautwein and PD Dr. Marco Skardelly summarize their study on the topic of metabolites in so-called diffuse gliomas on behalf of the entire research team. #Gliomas belong to the primary #tumors of the central nervous system. Mutations in the metabolic enzyme IDH1 are molecular alterations that play an important role in the diagnosis of tumors of the nervous system. The IDH1 protein performs an important task in the energy #metabolism of cells. In some #tumor cells, however, IDH1 is altered by a so-called point mutation, resulting in a new metabolic product called 2-HG, which alters many processes in the tumor cell. Scientists call such a thing an oncometabolite. For example, it upsets cellular metabolism and promotes cell division - the basis for #cancer is laid. Recent clinical trials in diffuse gliomas have identified the IDH1 mutation as a target for therapies. The therapeutic efficacy of these therapeutic approaches could perhaps be improved by understanding the metabolic changes that occur in association with IDH1 mutations. The present study used innovative methods to investigate the impact of IDH1 mutation on the metabolic profile of tumor tissues in a large clinical cohort. In addition, the researchers found tissue metabolites that could be candidate biomarkers, perhaps predicting clinical courses in the future. These candidate metabolites now need to be validated in prospective studies. Prof. Tabatabai, Dr. Trautwein and Dr. Skardelly present their research results in the video. Click here for the study: https://insight.jci.org/articles/view... © Universitätsklinikum Tübingen 🎥 https://immanuel-reimold.de/